Prevalence of Sarcopenia and Its Associated Factors in Patients With Knee Osteoarthritis in a Tertiary Care Hospital in Upper Egypt

NCT07566520 | Not Yet Recruiting

• 1 other identifier: Sarcopenia_OA_Assiut
• Study Type: observational
• Target: 224
• Locations: 1 country
• Sites: 1

Brief Summary

Osteoarthritis (OA) and sarcopenia are two highly prevalent, interconnected geriatric syndromes that often coexist, leading to a condition termed "osteosarcopenia". Globally, the pooled prevalence of sarcopenia in patients with knee OA is estimated at approximately 25.07%, significantly higher than in the general population.

Conditions

Osteoarthritis; Sarcopenia

Outcome Measures

Primary Outcomes (1)

• Prevalence of sarcopenia in knee osteoarthritis patients

  Prevalence of OA patients who meet the diagnostic criteria for sarcopenia (low muscle mass, strength, and physical performance) according to the European Working Group on Sarcopenia in Older People (EWGSOP2) revised consensus.

  at baseline

Secondary Outcomes (2)

• Nutritional Risk Assessment via Malnutrition Universal Screening Tool (MUST)

  Baseline

• The Quality of Life Factor (EQ-5D Index)

  Baseline

Study Arms (1)

Knee Osteoarthritis Patients

Adults aged 40 years and older diagnosed with knee osteoarthritis based on the American College of Rheumatology (ACR) criteria attending the Assiut University Trauma Hospital.

Eligibility Criteria

• Age: 40 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult patients aged 40 years and older, diagnosed with knee osteoarthritis, who are attending the Assiut University Trauma Hospital.

You may qualify if:

• Adults aged 40 years and older diagnosed with knee OA based on the American College of Rheumatology (ACR) criteria.

You may not qualify if:

• Inflammatory arthritis: patients with rheumatoid arthritis, gouty arthritis, or systemic lupus erythematosus (SLE) to avoid confusion with inflammatory muscle wasting.
• Physical Limitations: amputees or those with severe physical deformities preventing gait speed tests or handgrip measurement.
• Patients with cardiac pacemakers or implanted electronic devices (as these interfere with Bioelectrical Impedance Analysis (BIA)).
• Severe Comorbidities: end-stage renal or hepatic disease, advanced malignancy or cachexia.
• Severe neurological disorders (e.g., Parkinson's disease, Stroke with paralysis) that directly affect muscle mass and mobility.
• Prolonged use of systemic corticosteroids (which cause secondary sarcopenia)

Sponsors & Collaborators

• Assiut University: lead

Study Sites (1)

Assiut University Trauma Hospital

Asyut, Egypt

Location

MeSH Terms

Conditions

Osteoarthritis; Sarcopenia

Condition Hierarchy (Ancestors)

Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Muscular Atrophy; Neuromuscular Manifestations; Neurologic Manifestations; Nervous System Diseases; Atrophy; Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms; Signs and Symptoms

Central Study Contacts

Esraa M.H Ibrahim

CONTACT

+201112969235; esraa.m.hosny@aun.edu.eg

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Lecturer

Study Record Dates

• First Submitted: April 15, 2026
• First Posted: May 5, 2026
• Study Start: May 1, 2026
• Primary Completion (Estimated): April 1, 2027
• Study Completion (Estimated): July 1, 2027
• Last Updated: May 5, 2026

Record last verified: 2026-04

Locations

EG (1)